In This Article:
Over the last 7 days, the Australian market has remained flat with a notable 3.6% gain in the Financials sector, and it is up 10% over the past year with earnings forecasted to grow by 12% annually. In this context, identifying high growth tech stocks that align with these positive market conditions can be crucial for investors looking to capitalize on robust earnings potential and sector-specific momentum.
Top 10 High Growth Tech Companies In Australia
Name | Revenue Growth | Earnings Growth | Growth Rating |
---|---|---|---|
Clinuvel Pharmaceuticals | 22.41% | 27.42% | ★★★★★★ |
Pureprofile | 14.94% | 80.73% | ★★★★★☆ |
AVA Risk Group | 32.56% | 118.83% | ★★★★★★ |
DUG Technology | 10.90% | 32.21% | ★★★★★☆ |
Xero | 13.52% | 24.24% | ★★★★★☆ |
Careteq | 24.12% | 104.18% | ★★★★★☆ |
Adveritas | 57.98% | 144.21% | ★★★★★★ |
Wrkr | 33.39% | 124.86% | ★★★★★★ |
SiteMinder | 19.39% | 60.31% | ★★★★★☆ |
Senetas | 14.33% | 118.52% | ★★★★★☆ |
Click here to see the full list of 58 stocks from our ASX High Growth Tech and AI Stocks screener.
We'll examine a selection from our screener results.
Clinuvel Pharmaceuticals
Simply Wall St Growth Rating: ★★★★★★
Overview: Clinuvel Pharmaceuticals Limited is a biopharmaceutical company that develops and commercializes treatments for genetic, metabolic, systemic, and life-threatening disorders across Australia, Europe, the United States, Switzerland, and internationally with a market cap of A$760.68 million.
Operations: Clinuvel Pharmaceuticals generates revenue primarily from its biopharmaceutical sector, totaling A$88.18 million. The company focuses on developing and commercializing treatments for various disorders across multiple regions, including Australia, Europe, the United States, and Switzerland.
Clinuvel Pharmaceuticals reported a revenue increase of 14.87% to AUD 95.31 million for the year ending June 30, 2024, with net income rising to AUD 35.64 million, reflecting robust financial health. The company is exploring M&A opportunities and has significant R&D investments aimed at innovative treatments like afamelanotide for Parkinson’s Disease and vitiligo, underscoring its commitment to growth and medical advancements. Earnings are forecasted to grow at an impressive rate of 27.42% per year, outpacing the Australian market's average growth rate of 12.1%.
-
Dive into the specifics of Clinuvel Pharmaceuticals here with our thorough health report.
-
Assess Clinuvel Pharmaceuticals' past performance with our detailed historical performance reports.
Pro Medicus
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Pro Medicus Limited is a healthcare informatics company that develops and supplies imaging software and radiology information system (RIS) software and services to hospitals, imaging centers, and healthcare groups across Australia, North America, and Europe, with a market cap of A$15.72 billion.